JPWO2020058217A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020058217A5
JPWO2020058217A5 JP2021514556A JP2021514556A JPWO2020058217A5 JP WO2020058217 A5 JPWO2020058217 A5 JP WO2020058217A5 JP 2021514556 A JP2021514556 A JP 2021514556A JP 2021514556 A JP2021514556 A JP 2021514556A JP WO2020058217 A5 JPWO2020058217 A5 JP WO2020058217A5
Authority
JP
Japan
Prior art keywords
polypeptide
ulcers
administered
agent
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502359A (ja
JP2022502359A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/074767 external-priority patent/WO2020058217A1/en
Publication of JP2022502359A publication Critical patent/JP2022502359A/ja
Publication of JP2022502359A5 publication Critical patent/JP2022502359A5/ja
Publication of JPWO2020058217A5 publication Critical patent/JPWO2020058217A5/ja
Priority to JP2025077313A priority Critical patent/JP2025125558A/ja
Pending legal-status Critical Current

Links

JP2021514556A 2018-09-17 2019-09-17 皮膚科障害の処置のための薬剤 Pending JP2022502359A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077313A JP2025125558A (ja) 2018-09-17 2025-05-07 皮膚科障害の処置のための薬剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18194930.6 2018-09-17
EP18194930 2018-09-17
EP18203665.7 2018-10-31
EP18203665 2018-10-31
PCT/EP2019/074767 WO2020058217A1 (en) 2018-09-17 2019-09-17 Agent for treatment of dermatological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077313A Division JP2025125558A (ja) 2018-09-17 2025-05-07 皮膚科障害の処置のための薬剤

Publications (3)

Publication Number Publication Date
JP2022502359A JP2022502359A (ja) 2022-01-11
JP2022502359A5 JP2022502359A5 (https=) 2022-09-28
JPWO2020058217A5 true JPWO2020058217A5 (https=) 2022-09-28

Family

ID=67989007

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514556A Pending JP2022502359A (ja) 2018-09-17 2019-09-17 皮膚科障害の処置のための薬剤
JP2025077313A Pending JP2025125558A (ja) 2018-09-17 2025-05-07 皮膚科障害の処置のための薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077313A Pending JP2025125558A (ja) 2018-09-17 2025-05-07 皮膚科障害の処置のための薬剤

Country Status (11)

Country Link
US (2) US20220064243A1 (https=)
EP (1) EP3852785A1 (https=)
JP (2) JP2022502359A (https=)
KR (1) KR20210061388A (https=)
CN (1) CN113226350B (https=)
AU (1) AU2019343514B2 (https=)
BR (1) BR112021003820A2 (https=)
CA (1) CA3111158A1 (https=)
MA (1) MA53636A (https=)
MX (1) MX2021002983A (https=)
WO (1) WO2020058217A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536229A (ja) * 2020-07-27 2023-08-24 ヒューマン セル カンパニー Ｎｇｆバリアント、産生、組成物、及び治療的使用
CA3207296A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
ITRM20060367A1 (it) * 2006-07-13 2008-01-14 Lay Line Genomics Spa Muteine del hngf usi terapeutici e composizioni farmaceutiche
WO2010128519A1 (en) 2009-05-04 2010-11-11 Kumar C Jairaj A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Similar Documents

Publication Publication Date Title
AU2002334886B2 (en) Methods and compositions for treating dermal lesions
Davis et al. Pyoderma gangrenosum: skin grafting after preparation with hyperbaric oxygen
US20030185839A1 (en) Methods and compositions for treating dermal lesions
US6495158B1 (en) Acne patch
JP2007514750A5 (https=)
Hunt et al. Early tangential excision and immediate mesh autografting of deep dermal hand burns
AU2002334886A1 (en) Methods and compositions for treating dermal lesions
JP5469777B2 (ja) 糖尿病性足部潰瘍を処置するための方法
CN1251530A (zh) 具有催产素活性的物质在制备用于创伤愈合的药剂方面的应用
BR112012001491A2 (pt) composição de preparação externa para pele
JP2022502359A5 (https=)
RU2506092C2 (ru) Способ активирования лечения ран
US20230338296A1 (en) Devices and methods for delivery of oxygen to a wound
JPWO2020058217A5 (https=)
JP2007512377A5 (https=)
CN107446018B (zh) 促进伤口愈合的肽及其应用
Engel et al. Treprostinil for the treatment of severe digital necrosis in systemic sclerosis
KR20210024015A (ko) 상처 치유에 사용하기 위한 루브리신
RU2021110682A (ru) Средство для лечения дерматологических заболеваний
Liu et al. The therapeutic effects of basic fibroblast growth factor in nasal vestibulitis
Yoon et al. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane
JP2021527645A5 (https=)
Canter Conservative management of wounds
JP3882943B2 (ja) 瘢痕形成剤としてのコンポーネントｂ
WO2012126047A1 (en) Agent and method for treating pain and reducing inflammation